RecruitingNCT06874231

Brain Connectivity Marker for Alzheimer's Disease

Clinical Application of a Brain Connectivity Marker for Early Detection of Alzheimer's Disease


Sponsor

Karolinska Institutet

Enrollment

120 participants

Start Date

Apr 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).


Eligibility

Min Age: 40 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating brain connectivity patterns in people across the spectrum of Alzheimer's disease — from those who just report memory concerns to those with mild cognitive impairment and confirmed Alzheimer's — to identify early markers of the disease. **You may be eligible if...** - You live in Sweden and speak Swedish - You have concerns about your memory (but no confirmed diagnosis), OR have mild cognitive impairment with abnormal Alzheimer's biomarkers in spinal fluid, OR have a confirmed diagnosis of Alzheimer's disease - Your memory test scores (MMSE or MoCA) fall within the range required for your group **You may NOT be eligible if...** - You have dementia from a cause other than Alzheimer's disease - Your memory test scores are outside the range for your specific group - You do not speak or understand Swedish Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNeuroimaging

The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples


Locations(1)

Karolinska University Hospital

Stockholm, Solna, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06874231


Related Trials